PRASAD IYER: I'm Prasad Iyer, a consultant and professor in the division of gastroenterology and hepatology at Mayo Clinic in Rochester, Minnesota. I lead the Barrett's esophagus interventional unit and also direct the esophageal diseases interest group. The Barrett's esophagus interventional unit is also staffed by two advanced practice providers and four registered nurses, all dedicated to the care and treatment of patients with Barrett's esophagus and esophageal cancer.
We also collaborate very closely with a multidisciplinary group of expert GI pathologists, thoracic surgeons, radiation and medical oncologists to provide optimal care for patients with dysplastic Barrett's and esophageal cancer. It is my distinct pleasure to introduce Dr. Cadman Leggett, who has recently joined the Barrett's esophagus interventional unit.
CADMEN LEGGETT: Dr. Iyer, thank you for your kind introduction. A diagnosis of Barrett's esophagus can be unsettling to many patients. And it is our priority to help our patients gain a deep understanding of their diagnosis and treatment options. I have a strong academic interest in the diagnosis and management of Barrett's esophagus. In particular, the application of advanced imaging modalities for the diagnosis of Barrett's esophagus-related dysplasia.
This includes the use of digital chromoendoscopy, optical coherence tomography, and confocal laser endomicroscopy.
PRASAD IYER: In addition to excellent clinical care, the Barrett's esophagus unit is also actively engaged in clinical and translational research. Several research protocols and trials funded by the NIH and other funding agencies focused on non-endoscopic screening, biomarker development, and novel endoscopic therapeutic modalities for dysplastic Barrett's are being run by physicians in this group. Our group is also pioneering techniques in artificial intelligence for the endoscopic and histologic diagnosis of dysplasia in Barrett's esophagus.
CADMEN LEGGETT: Perhaps one of the most important aspects of our practice is the longitudinal follow-up we provide our patients. Our team is here to ensure that all patients with Barrett's esophagus who undergo endoscopic therapy are followed appropriately, with the ultimate goal of helping them reach complete eradication of intestinal metaplasia.
PRASAD IYER: Both Dr. Leggett and myself encourage you to contact us directly via email or by phone. We look forward to partnering with you to provide excellent clinical care to each and every one of your patients. Thank you so much.
[MUSIC PLAYING]
